CBUS

Cibus, Inc.

Healthcare
Biotechnology
$120M market cap

Forecast run · Sep 14, 2026Upside rank 278 of 3,136

Model Signal

ForecastQ Daily Probabilities

62.9%

48.2%

45.2%

Analyst Consensus

Recommendation2.25/5 Buy

Last price$1.57

Price target$11.50

Implied move+632.5%

Analysts4

ForecastQ Portfolios

CBUS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.